Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Research

Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes

Tony Wawina-Bokalanga, Bert Vanmechelen, Valentine Lhermitte, Joan Martí-Carreras, Valentijn Vergote, Fara Raymond Koundouno, Joseph Akoi-Boré, Ruth Thom, Tom Tipton, Kimberley Steeds, Kéita Balla Moussa, Ablam Amento, Lies Laenen, Sophie Duraffour, Martin Gabriel, Paula Ruibal, Yper Hall, Mandy Kader-Kondé, Stephan Günther, Guy Baele, Cesar Muñoz-Fontela, Johan Van Weyenbergh, Miles W. Carroll, and Piet MaesComments to Author 
Author affiliations: KU Leuven, Leuven, Belgium (T. Wawina-Bokalanga, B. Vanmechelen, V. Lhermitte, J. Martí-Carreras, V. Vergote, L. Laenen, G. Baele, J. Van Weyenbergh, P. Maes); University Julius Nyerere of Kankan, Conakry, Guinea (F.R. Koudouno); Institut National de Santé Publique, Conakry (J. Akoi-Boré); Public Health England, Salisbury, UK (R. Thom, T. Tipton, K. Steeds, Y. Hall, M.W. Carroll); Centre d'Excellence de Formation et Recherche sur les Maladies Prioritaires en Guinée, Conakry (K.B. Moussa, A. Amento, M. Kader-Kondé); German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Germany (S. Duraffour, M. Gabriel); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (S. Duraffour, M. Gabriel, P. Ruibal, S. Günther, C. Muñoz-Fontela)

Main Article

Table 1

Frequency of KIR genes and HLA class I alleles among control group, Ebola survivors, and persons who died of Ebola virus disease, Guinea, 2015–2017*

Gene Controls, no. (%) Survivors, no. (%) Persons who died, no. (%) p value
Inhibitory KIRs
2DL1 77 (100.0) 101 (100.0) 119 (100.0)
2DL2 67 (87.0) 99 (98.0) 99 (83.2) †‡
2DL3 71 (92.2) 94 (93.1) 112 (94.1)
2DL4 77 (100.0) 100 (99.0) 118 (99.1)
2DL5 42 (54.5) 47 (46.5) 75 (63.0)
3DL1 77 (100.0) 101 (100.0) 118 (99.1)
3DL2 76 (98.7) 101 (100.0) 119 (100.0)
3DL3
77 (100.0)
101 (100.0)
119 (100.0)

Activating KIRs
2DS1 46 (59.7) 55 (54.4) 74 (62.2)
2DS2 37 (48.0) 46 (45.5) 55 (46.2)
2DS3 23 (29.8) 30 (29.7) 40 (33.6)
2DS4–001 70 (90.9) 94 (93.1) 103 (86.6)
2DS4–003 40 (51.9) 41 (40.6) 67 (56.3)
2DS5 23 (29.8) 26 (25.7) 40 (33.6)
3DS1
5 (6.5)
4 (3.9)
13 (10.9)

Pseudogenes
2DP1 77 (100.0) 100 (99.0) 116 (97.5)
3DP1–001 6 (7.8) 4 (3.9) 8 (6.7)
3DP1–004
76 (98.7)
99 (98.0)
117 (98.3)

HLA class I alleles
HLA-C1Asn80 55 (71.4) 78 (77.2) 85 (71.4)
HLA-C2Lys80 58 (75.3) 74 (73.3) 88 (73.9)
HLA-B-Bw4Thr80 8 (10.4) 9 (8.9) 22 (18.5)
HLA-B-Bw4Ile80 33 (42.8) 48 (47.5) 38 (31.9)
HLA-A-Bw4 23 (29.8) 26 (25.7) 37 (31.1)

*Frequency (%) of each KIR gene or HLA class I allele was calculated and defined as the number of individuals having the gene or allele divided by the number of persons in the studied group. HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; Pc, corrected p value.
†p value <Pc (survivors vs. persons who died).
‡p value <Pc (controls vs. survivors).

Main Article

Page created: October 16, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external